Cambridge Regulatory Services

cambreg.co.uk

Regulatory Affairs Specialists with clients ranging from start-up biotechs to multinational pharmaceutical companies. Cambridge Regulatory Services has expertise and.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

SENSYNE HEALTH AND PHESI FORM A JOINT COMMERCIAL DEVELOPMENT PARTNERSHIP WITH A LEADING PHARMACEUTICAL COMPANY

Sensyne Health, Phesi | May 24, 2021

news image

Sensyne Health plc, the Clinical AI company, today announced that it has entered a joint commercial clinical development partnership in an undisclosed disease area with a major pharmaceutical company that is an existing client of Phesi with its U.S.-based strategic partner Phesi Inc. Sensyne and Phesi have entered into a joint commercial collaboration with a pharmaceutical customer for the first time since forming a strategic alliance in January 2021. The development work will con...

Read More

Pharma Tech

WUXI ATU ANNOUNCES LICENSING AGREEMENT WITH JANSSEN FOR TESSA™ TECHNOLOGY

WuXi AppTec | August 12, 2022

news image

WuXi Advanced Therapies a wholly owned subsidiary of WuXi AppTec, announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral vectors than traditional AAV manufacturing systems. Janssen will also have access to work on WuXi ATU's proprietary clonal suspens...

Read More

Business Insights

SCA PHARMA NAMES LOUIS PACE AS CHIEF FINANCIAL OFFICER AND CHIEF INFORMATION OFFICER

SCA Pharma | July 15, 2022

news image

SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L leadership roles. Most recently, Mr. Pace served as Chief Financial Officer at Orchid O...

Read More

Business Insights

GLAUKOS ANNOUNCES MORE THAN 1 MILLION ISTENT® TECHNOLOGIES IMPLANTED WORLDWIDE

Glaukos | September 12, 2022

news image

Glaukos Corporation an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases announced a significant milestone as its iStent® family of technologies have now been implanted in more than one million procedures worldwide. This market-leading milestone is a testament to the decades of investment from Glaukos as the corporate founder and pioneer of the now well-established micro-invasive glaucoma ...

Read More
news image

Pharmacy Market

SENSYNE HEALTH AND PHESI FORM A JOINT COMMERCIAL DEVELOPMENT PARTNERSHIP WITH A LEADING PHARMACEUTICAL COMPANY

Sensyne Health, Phesi | May 24, 2021

Sensyne Health plc, the Clinical AI company, today announced that it has entered a joint commercial clinical development partnership in an undisclosed disease area with a major pharmaceutical company that is an existing client of Phesi with its U.S.-based strategic partner Phesi Inc. Sensyne and Phesi have entered into a joint commercial collaboration with a pharmaceutical customer for the first time since forming a strategic alliance in January 2021. The development work will con...

Read More
news image

Pharma Tech

WUXI ATU ANNOUNCES LICENSING AGREEMENT WITH JANSSEN FOR TESSA™ TECHNOLOGY

WuXi AppTec | August 12, 2022

WuXi Advanced Therapies a wholly owned subsidiary of WuXi AppTec, announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral vectors than traditional AAV manufacturing systems. Janssen will also have access to work on WuXi ATU's proprietary clonal suspens...

Read More
news image

Business Insights

SCA PHARMA NAMES LOUIS PACE AS CHIEF FINANCIAL OFFICER AND CHIEF INFORMATION OFFICER

SCA Pharma | July 15, 2022

SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L leadership roles. Most recently, Mr. Pace served as Chief Financial Officer at Orchid O...

Read More
news image

Business Insights

GLAUKOS ANNOUNCES MORE THAN 1 MILLION ISTENT® TECHNOLOGIES IMPLANTED WORLDWIDE

Glaukos | September 12, 2022

Glaukos Corporation an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases announced a significant milestone as its iStent® family of technologies have now been implanted in more than one million procedures worldwide. This market-leading milestone is a testament to the decades of investment from Glaukos as the corporate founder and pioneer of the now well-established micro-invasive glaucoma ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us